There were 414 press releases posted in the last 24 hours and 203,973 in the last 365 days.

Marburg Virus Disease Pipeline Offers Promising New Options for Treatment

Around 12+ key companies are developing the Marburg Virus Disease therapies. Bavarian Nordic is developing the MVA-BN filovirus vaccine, which is in the most advanced stage.

/EIN News/ -- Los Angeles, USA, June 16, 2021 (GLOBE NEWSWIRE) -- Marburg Virus Disease Pipeline Offers Promising New Options for Treatment

Around 12+ key companies are developing the Marburg Virus Disease therapies. Bavarian Nordic is developing the MVA-BN filovirus vaccine, which is in the most advanced stage. 

DelveInsight’s “Marburg Virus Disease Pipeline Insight” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the Marburg Virus Disease pipeline landscapes. It comprises Marburg Virus Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Marburg Virus Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Marburg Virus Disease pipeline products.     

Some of the key takeaways from the Marburg Virus Disease Pipeline Report  

  • Notable companies such as Bavarian Nordic, BioCryst Pharmaceuticals, Integrated Biotherapeutics, Geovax, Batavia Biosciences, Globavir Biosciences, Collaboration Pharmaceuticals, Emergex Vaccines, ReiThera, Emergent BioSolutions, Mapp Biopharmaceuticals, Biofactura, Alkido Pharma, Flow Pharma, and others are developing potential drug candidates to improve the Marburg Virus Disease treatment scenario. 
  • BioCryst is developing galidesivir in partnership with U.S. government agencies and other institutions. In September 2013, the National Institute of Allergy and Infectious Diseases (NIAID) contracted with BioCryst to develop galidesivir to treat Marburg virus disease and potentially for other filoviruses, including the Ebola virus.
  • Integrated BioTherapeutics Inc. (IBT), in May 2021, announced the receipt of a contract valued at up to USD 16.3 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop IBT-T03H, a monoclonal antibody for the treatment of Marburg virus disease (MVD).
  • BioFactura is developing a Marburg therapeutic in close collaboration with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). 
  • Batavia Biosciences has partnered with IAVI under an award they have received from the US Defense Threat Reduction Agency (DTRA) to develop a VSV-based vaccine against the Marburg virus. The VSV-Marburg vaccine candidate rVSVΔG-MARV-GP has been licensed by IAVI from the Public Health Agency of Canada and demonstrated strong protection from the deadly disease in non-human primate studies. 
  • Mapp Biopharmaceutical, Inc. has been given an advanced research and development contract for USD 16.5 million with options for an additional USD 30.0 million by the Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health and Human Services (HHS) to advance MBP091 through the completion of Phase 1 clinical trial. MBP091 is a single human monoclonal antibody (mAb) developed as a pan-Marburg virus therapeutic for the treatment of hemorrhagic fevers that are caused by Marburg and the closely related Ravn virus. 

Get an overview of pipeline landscape @ Marburg Virus Disease Clinical Trials Analysis 

Marburg Virus Disease is a highly virulent disease, which causes hemorrhagic fever. It belongs to the same family that causes Ebola virus disease. There is no particular treatment for Marburg hemorrhagic fever. Instead, supportive hospital therapy should be utilized, including balancing the patient’s fluids and electrolytes, maintaining oxygen status and blood pressure, replacing lost blood and clotting factors, and treating any complicating infections. 

Marburg Virus Disease Emerging Drugs

  • Galidesivir: BioCryst Pharmaceuticals

Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the virus treatment. BioCryst is developing galidesivir in partnership with U.S. government agencies and other institutions. In September 2013, NIAID contracted with BioCryst to develop galidesivir to treat Marburg Virus Disease and potentially for other filoviruses, including the Ebola virus. The drug is currently in phase 1 of clinical trials for the treatment of Marburg Virus Disease.

Research and Development 
Phase I 
NCT03800173: BioCryst Pharmaceuticals, in December 2018, initiated “A Phase 1 Double-blind, Placebo Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Galidesivir (BCX4430) Administered as Single Doses Via Intravenous Infusion in Healthy Subjects”. This is a placebo-controlled, randomized, double-blind study to evaluate the pharmacokinetics of galidesivir following administration of single doses by IV infusion. This single ascending dose study will assess the safety, tolerability, and PK of single doses of galidesivir vs. placebo administered as IV infusions in healthy subjects enrolled in up to four dose cohorts of 8 subjects each. A single dose of study drug will be administered per cohort: 6 subjects will receive galidesivir IV, and two subjects will receive matching placebo. The trial got completed in April 2019 with 32 enrolled participants.

Results 

  • Galidesivir was safe and generally well-tolerated in Phase 1 clinical safety and pharmacokinetics trials by intravenous and intramuscular administration routes in normal subjects. In animal studies, galidesivir has demonstrated survival benefits against various serious pathogens, comprising Ebola, Marburg, Yellow Fever, and Zika viruses. 
  • Galidesivir has also shown broad-spectrum activity in vitro against more than 20 ribonucleic acids (RNA) viruses in nine different families, comprising coronaviruses, filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, and flaviviruses.
  • MVA-BN filovirus vaccine: Bavarian Nordic

MVA-BN Filo is a multivalent vaccine candidate designed to protect against the most common causes of viral hemorrhagic fever; Ebola and the Marburg virus. While several sub-types of Ebola are known, the vaccine targets the Zaire and Sudan strains, which are considered the most important from a public health perspective in addition various. It is currently in phase 2 of clinical trials for the treatment of Marburg Virus Disease.

  • cAd3-Marburg: ICON plc

cAd3-Marburg, also known as VRC MARADC087 00 VP, is being developed and investigated by Albert B. Sabin Vaccine Institute, ICON plc, and Oklahoma Blood Institute in Phase I stage of development for the treatment of patients with Marburg virus disease.

Research and Development 
Phase I
NCT04723602: In January 2021, a trial was initiated by ICON plc in collaboration with Sabin vaccine institute titled “Phase 1b Trial to Evaluate Safety, Tolerability and Immune Responses of 2 Monovalent Chimpanzee Adenoviral Vectored Filovirus (Ebola-S and Marburg) Vaccines to Healthy Adults, Collection of Plasma/Serum for the Purposes of Assay Development”. The primary objective is to evaluate the safety and tolerability of cAd3-EBO-S and cAd3 Marburg vaccines when administered Intramuscular (IM) at a dose of 1 x 10^11 particle units (PU) to healthy adults. The trial is anticipated to get completed in December 2021 with an estimated enrollment of 32 participants.

For further information, refer to the detailed report @ Marburg Virus Disease Pipeline Therapeutics 

Scope of Marburg Virus Disease Pipeline Drug Insight    

  • Coverage: Global 
  • Major Players: 12+ Key Players
  • Prominent Players: Bavarian Nordic, BioCryst Pharmaceuticals, Integrated Biotherapeutics, Geovax, Batavia Biosciences, Globavir Biosciences, Collaboration Pharmaceuticals, Emergex Vaccines, ReiThera, Emergent BioSolutions, Mapp Biopharmaceuticals, Biofactura, Alkido Pharma, Flow Pharma, and many others.   
  • Key Drugs Profiles: 12+ Products
  • Phases:  

·       Marburg Virus Disease Therapies Late-stage (Phase III)  
·       Marburg Virus Disease Therapies Mid-stage (Phase II)
·       Marburg Virus Disease Therapies Early-stage (Phase I) 
·       Marburg Virus Disease Pre-clinical stage and Discovery candidates     
·       Discontinued and Inactive candidates 

  • Mechanism of Action:

·        RNA replicase inhibitors
·     Immunostimulants
·     Virus replication inhibitors

  • Molecule Types:   

·       Peptides
·       Monoclonal Antibody
·       Polymer
·       Small molecule
·       Gene therapy 

  • Route of Administration:

·       Oral
·       Parenteral
·       Intravenous
·       Subcutaneous
·       Topical 

  • Product Types:

·       Monotherapy
·       Combination
·       Mono/Combination 

Key Questions regarding Current Marburg Virus Disease Treatment Landscape and Emerging Therapies Answered in the Pipeline Report  

  • What are the current options for Marburg Virus Disease treatment?
  • How many companies are developing therapies for the treatment of Marburg Virus Disease? 
  • How many are Marburg Virus Disease emerging therapies in the early-stage, mid-stage, and late development stages to treat Marburg Virus Disease? 
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the Marburg Virus Disease market? 
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Marburg Virus Disease?  
  • What are the current novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Marburg Virus Disease therapies? 
  • What are the critical designations that have been granted for the emerging therapies for Marburg Virus Disease? 
  • How many patents are granted and pending for the emerging therapies to treat Marburg Virus Disease?   

Table of Contents

1 Marburg Virus Disease Report Introduction
2 Marburg Virus Disease Executive Summary
3 Marburg Virus Disease Overview
4 Marburg Virus Disease – DelveInsight’s Analytical Perspective In-depth Commercial Assessment
5 Marburg Virus Disease Pipeline Therapeutics
6 Marburg Virus Disease Late Stage Products (Phase III)
7 Marburg Virus Disease Mid Stage Products (Phase II)
7.1 MVA-BN filovirus vaccine: Bavarian Nordic
8 Marburg Virus Disease Early Stage Products (Phase I)
8.1 BCX-4430: BioCryst Pharmaceuticals
9 Marburg Virus Disease Preclinical Stage Products
9.1 Universal Filovirus vaccine (Marburg): Emergex Vaccines
10 Marburg Virus Disease Therapeutic Assessment
11 Marburg Virus Disease Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Marburg Virus Disease Key Companies
14 Marburg Virus Disease Key Products
15 Marburg Virus Disease Unmet Needs
16 Marburg Virus Disease Market Drivers and Barriers
17 Marburg Virus Disease Future Perspectives and Conclusion
18  Marburg Virus Disease Analyst Views
19 Appendix
20 About DelveInsight

Get a customized pipeline report @ Marburg Virus Disease Drugs Pipeline Report  

Related Reports 

DelveInsight's 'Central Venous Catheters Market Insights, Competitive Landscape and Market Forecast-2026' report delivers an in-depth understanding of Central Venous Catheters.

DelveInsight’s Juvenile Idiopathic Arthritis (JIA) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

DelveInsight's Keloid - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. 

"Oncolytic Virus Cancer Therapy" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action.

Capnography Devices Market Insights, Competitive Landscape, and Market Forecast-2026 report delivers an in-depth understanding of Capnography Devices and the historical and forecasted epidemiology. 

Cardiac Resynchronization Therapy Market Insights, Competitive Landscape, and Market Forecast-2026 report delivers an in-depth understanding of Cardiac Resynchronization Therapy. 

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.


Contact Us:

Shruti Thakur 

info@delveinsight.com   

+1(919)321-6187 

www.delveinsight.com 

Primary Logo